Bank of Montreal’s Immuneering IMRX Stock Holding History

Bank of Montreal’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-714,037	Closed	-$8M	–	4017
2023 Q2	$8M	Buy	714,037 +618,009	+644%	+$5.94M	﹤0.01%	1111
2023 Q1	$1.01M	Buy	+96,028	New	+$545K	﹤0.01%	2043

Other funds holding IMRX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return

Bank of Montreal's IMRX Position: Q3 2023 in Review

Bank of Montreal sold out of Immuneering (IMRX) in Q3 2023, closing a stake of 714,037 shares — an estimated $8M sold.

Bank of Montreal first reported a position in IMRX in Q1 2023 and held it in 2 quarters. The position peaked at $8M in Q2 2023. 52 funds tracked by Wall St. Rank hold IMRX as of Q3 2023.

Bank of Montreal reported no remaining Immuneering position as of Q3 2023 after selling out during the quarter.
Bank of Montreal sold 714,037 Immuneering shares in Q3 2023, an estimated $8M.
Bank of Montreal first reported a position in Immuneering in Q1 2023 and held it in 2 quarters.
Bank of Montreal's Immuneering position peaked at $8M in Q2 2023.
52 funds tracked by Wall St. Rank held Immuneering as of Q3 2023.

Based on Bank of Montreal's 13F filing for Q3 2023, filed 1 Nov 2023.